NCI-2022-05160

A Phase III, Randomised, Open-Label Study of Savolitinib inCombination With Osimertinib Versus Platinum-Based DoubletChemotherapy in Participants With EGFR MutatedMET-Overexpressed and/or Amplified, Locally Advanced orMetastatic Non-Small Cell Lung Cancer Who Have Progressed onTreatment With Osimertinib (SAFFRON)

The SAFFRON study is a Phase 3 randomized, open-label clinical trial comparing savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced, or metastatic non-small cell lung cancer (NSCLC) who have progressed on treatment with osimertinib. Savolitinib is a selective MET inhibitor that targets tumors with MET alterations, while osimertinib is an EGFR tyrosine kinase inhibitor commonly used in EGFR-mutated NSCLC. This study aims to evaluate the efficacy and safety of combining savolitinib with osimertinib compared to standard chemotherapy in this specific patient population.

Phase 3: A phase 3 clinical trial is a large-scale study designed to assess the effectiveness and safety of a new medical treatment or approach compared to a standard treatment

EGFR mutated: Epidermal Growth Factor Receptor (EGFR) is on the surface of cells and helps them grow and divide. In cancer, EGFR is like a switch that gets stuck in the "on" position, making cells grow and divide too much.

MET-overexpressed: This protein is involved in regulating cell growth, survival, and movement. In cancer, MET overexpression can contribute to tumor growth, invasion, and spread, making it a potential target for therapy.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05261399

Clinical Trial Site: Columbia

To see all available clinical trials click here.